Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hVIVO, part of Open Orphan plc, to accelerate the development of a Broad-Spectrum ‘Universal’ Influenza Vaccine, FLU-v, and a Mosquito-Borne Diseases Vaccine, AGS-v.
The development of the FLU-v Universal Flu Vaccine and the AGS-v Mosquito-Borne Diseases vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.
Imutex is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate development of both vaccines.
Company Details
- Employees
- 2
- Founded
- -
- Phone
- +44 207 036 8550
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- imutex.com
- Keywords
- European Green Transition.
Imutex Ltd Questions
Imutex Ltd's helpline number is +44 207 036 8550
Imutex Ltd's website is imutex.com
Imutex Ltd's LinkedIn profile is https://uk.linkedin.com/company/imutex-limited
Imutex Ltd has
2 employees.
View email and phone details for 2
employees at Imutex Ltd.
Imutex Ltd's industry is
Pharmaceutical Manufacturing
Imutex Ltd's top competitors are
Rfi Group,
Pds Biotechnology,
Conserv Bioscience,
Proverum,
Poolbeg Pharma Plc,
Raglan Capital,
Superganix™,
European Green Transition,
Samsara Therapeutics,
Hvivo.
Imutex Ltd's categories are Pharmaceutical Manufacturing
Imutex Ltd's founding year is 2016
